Müllerian aplasia and hyperandrogenism

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:247768OMIM:158330Q51.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Müllerian aplasia and hyperandrogenism (also known as Müllerian duct aplasia with hyperandrogenism) is an extremely rare condition characterized by the combination of absent or severely underdeveloped Müllerian duct-derived structures (uterus, fallopian tubes, and upper vagina) in 46,XX individuals, along with signs of excess androgen activity. Affected individuals are genetically female but present with primary amenorrhea (absence of menstruation) due to the absence of a functional uterus, while typically having normal female external genitalia and normal ovarian function otherwise. The hyperandrogenism component may manifest as hirsutism (excess body hair), acne, and elevated androgen levels in the blood, which can overlap clinically with features seen in polycystic ovary syndrome (PCOS). This condition affects the reproductive system primarily, with the Müllerian structures failing to develop properly during embryogenesis. The hyperandrogenism suggests an underlying hormonal dysregulation that distinguishes this entity from isolated Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, which involves Müllerian aplasia without androgen excess. The exact molecular etiology remains poorly understood, though the co-occurrence of these two features suggests a shared developmental or genetic pathway may be disrupted. Diagnosis is typically made during adolescence when affected individuals are evaluated for primary amenorrhea. Imaging studies such as pelvic ultrasound or MRI confirm the absence of the uterus and may reveal normal ovaries. Management is multidisciplinary and may include vaginal dilation therapy or surgical creation of a neovagina to allow sexual intercourse, as well as anti-androgen therapy or other hormonal treatments to manage hyperandrogenism symptoms. Fertility is not possible through natural conception due to the absence of a uterus, though assisted reproductive technologies with gestational surrogacy may be an option for genetic parenthood.

Also known as:

Clinical phenotype terms— hover any for plain English:

Hypoplasia of the uterusHP:0000013Abnormality of the ovaryHP:0000137Abnormal vagina morphologyHP:0000142Shield chestHP:0000914Frontal baldingHP:0002292High anterior hairlineHP:0009890
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Juvenile

Begins in the teen years

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Müllerian aplasia and hyperandrogenism.

View clinical trials →

No actively recruiting trials found for Müllerian aplasia and hyperandrogenism at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Müllerian aplasia and hyperandrogenism community →

No specialists are currently listed for Müllerian aplasia and hyperandrogenism.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Müllerian aplasia and hyperandrogenism.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Müllerian aplasia and hyperandrogenismForum →

No community posts yet. Be the first to share your experience with Müllerian aplasia and hyperandrogenism.

Start the conversation →

Latest news about Müllerian aplasia and hyperandrogenism

No recent news articles for Müllerian aplasia and hyperandrogenism.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Müllerian aplasia and hyperandrogenism

What is Müllerian aplasia and hyperandrogenism?

Müllerian aplasia and hyperandrogenism (also known as Müllerian duct aplasia with hyperandrogenism) is an extremely rare condition characterized by the combination of absent or severely underdeveloped Müllerian duct-derived structures (uterus, fallopian tubes, and upper vagina) in 46,XX individuals, along with signs of excess androgen activity. Affected individuals are genetically female but present with primary amenorrhea (absence of menstruation) due to the absence of a functional uterus, while typically having normal female external genitalia and normal ovarian function otherwise. The hyper

How is Müllerian aplasia and hyperandrogenism inherited?

Müllerian aplasia and hyperandrogenism follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Müllerian aplasia and hyperandrogenism typically begin?

Typical onset of Müllerian aplasia and hyperandrogenism is juvenile. Age of onset can vary across affected individuals.